16. NMA results for PFS (IMDC intermediate and poor risk groups).

Results of network meta‐analysis for outcome progression‐free survival (IMDC intermediate and poor risk groups). Treatments are ordered by P‐Score (descending). Only subnetworks with >1 designs. Upper triangle: direct estimate. Lower triangle: network estimate. Subnet 1 No. of studies: 11. No. of pairwise comparisons: 11. No. of treatments: 7. No. of designs: 6 Heterogeneity/Inconsistency: Q = 8.7, df = 5, P = 0.12; I² = 42.5%, Tau² = 0.0357 Treatment Effects + 95%‐CIs (Hazard ratios, random‐effects model):
LEN+PEM	.		.		.	.		.		0.36 [0.24, 0.54]
0.78 [0.40, 1.52]	CAB		.		.	.		.		0.46 [0.27, 0.79]
0.75 [0.43, 1.29]	0.96 [0.51, 1.81]		NIV+CAB		.	.		.		0.48 [0.34, 0.69]
0.60 [0.35, 1.02]	0.77 [0.41, 1.45]		0.81 [0.50, 1.32]		AVE+AXI	.		.		0.60 [0.43, 0.84]
0.52 [0.30, 0.92]	0.67 [0.35, 1.29]		0.70 [0.42, 1.18]		0.87 [0.52, 1.44]	LEN+EVE		.		0.69 [0.47, 1.01]
0.49 [0.27, 0.87]	0.63 [0.32, 1.22]		0.65 [0.38, 1.13]		0.81 [0.48, 1.37]	0.93 [0.53, 1.63]		NIV+IPI		0.74 [0.49, 1.11]
0.36 [0.24, 0.54]	0.46 [0.27, 0.79]		0.48 [0.34, 0.69]		0.60 [0.43, 0.84]	0.69 [0.47, 1.01]		0.74 [0.49, 1.11]		SUN
Subnet 2 No. of studies: 5. No. of pairwise comparisons: 5. No. of treatments: 5. No. of designs: 4 Heterogeneity/Inconsistency: Q 0.47, df = 1, P = 0.50; I² = 0%, Tau² = 0.0 Treatment Effects + 95%‐CIs (Hazard ratios, random‐effects model):
PAZ		0.73 [0.45, 1.19]		.			.		.
0.73 [0.45, 1.19]		TEM		.			.		0.74 [0.60, 0.91]
0.71 [0.40, 1.25]		0.97 [0.73, 1.31]		IFN+TEM			.		0.76 [0.62, 0.94]
0.56 [0.32, 0.98]		0.76 [0.57, 1.02]		0.78 [0.58, 1.05]			NAP+IFN		0.97 [0.79, 1.19]
0.54 [0.32, 0.92]		0.74 [0.60, 0.91]		0.76 [0.62, 0.94]			0.97 [0.79, 1.19]		IFN